PFS and OS
PD
EVENTS
As of December 6, 2019, 46 patients experienced endpoint events (PD) and 10 were censored (six patients received surgical treatment and four were lost to follow-up). Median PFS values were 6.9 months [95% confidence interval (CI), 4.3–8.8] in the CIK-SOX group and 4.9 months [95% CI, 3.6–7.7] in the SOX group (hazard ratio (HR) 0.80, Progression-free survival. As of December 6, 2019, six patients in the CIK-SOX group and four patients in the SOX groups survived, and their median follow-up time was 47.3 and 41.2 months, respectively. Median OS for the CIK-SOX and SOX groups was 17.8 months (95% CI, 10.2–24.3) and 9.75 months (95% CI, 6.4–16.5; HR 0.76, Overall survival. The median number of cell therapy cycle in the CIK-SOX group was 5. Twenty-eight patients with no fewer than 3 cell therapy cycles and twenty-five patients with no fewer than 4 cell therapy cycles. In terms of PFS (PFS of the number of cell therapy cycle. OS of the number of cell therapy cycle. 